Abstract
Obesity is strongly associated with nonalcoholic fatty liver disease as well as advanced
forms of the disease such as nonalcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular
carcinoma. While lifestyle and diet modifications have been the cornerstone of treatment
for NASH thus far, they are only effective for less than half of the patients. New
endoscopic bariatric therapies (EBTs) have already proved to be safe and effective
for the treatment of obesity and type 2 diabetes mellitus, and may provide an intermediate,
less invasive, cost-effective option for patients with NASH. In this review, we aim
to describe the data and evidence as well as outline future areas of development for
endobariatric therapies for the treatment of NASH. In conclusion, EBTs present an
effective and safe therapeutic modality for use in the growing pandemic of obesity-related
liver disease and should be investigated further with large-scale trials in this patient
population.
Keywords
endoscopic bariatric and metabolic therapies - weight loss - nonalcoholic steatohepatitis
- metabolic effects - obesity
